Nuvation Bio Inc. NUVB
Set alert
At close · Oct 30
After hours · Oct 30, 5:39 PM ET
- YTD
- -46.88%
- 1 year
- -7.57%
- Open
- 4.75
- Prev close
- 4.77
- Mkt cap
- 1.67B
- Vol
- 5.06M
- Avg vol
- 5.35M
- EPS
- -0.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.60
- High
- 4.81
- Forward P/E
- -317.00
- Beta
- 1.62
- Short ratio
- 11.57
- Inst. own
- 67.84%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 5.68
- 200-d avg
- 5.41
- 1y target
- 13.00
5D chart
Signals (92)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:25 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| RSI: Oversold | Oct 27, 2:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
-
3 days ago benzinga.com
Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519)…
3 days ago prnewswire.com
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
New sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a…
1 week ago prnewswire.com
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today…
1 month ago benzinga.com
This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).
1 month ago defenseworld.net
Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street Analysts
Shares of Nuvation Bio Inc. (NYSE: NUVB - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve analysts that are currently covering the company, Marketbeat.com reports.…
-
1 month ago benzinga.com
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
1 month ago benzinga.com
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.
-
1 month ago benzinga.com
Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes to the safety sections of labeling with longer follow-up and no new safety signals…
1 month ago prnewswire.com
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified…
-
1 month ago benzinga.com
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target
Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
1 month ago seekingalpha.com
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1…
1 month ago prnewswire.com
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1…
1 month ago seekingalpha.com
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
1 month ago benzinga.com
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”
1 month ago benzinga.com
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.
1 month ago zacks.com
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the…
2 months ago prnewswire.com
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David…
2 months ago zacks.com
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago benzinga.com
This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
2 months ago benzinga.com
This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.
2 months ago benzinga.com
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
-
2 months ago benzinga.com
Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant…
2 months ago prnewswire.com
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma…
2 months ago zacks.com
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
-
2 months ago benzinga.com
JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13
JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating and announces Price Target of $13.
2 months ago defenseworld.net
Critical Analysis: Pathfinder Cell Therapy (OTCMKTS:PFND) and Nuvation Bio (NYSE:NUVB)
Nuvation Bio (NYSE: NUVB - Get Free Report) and Pathfinder Cell Therapy (OTCMKTS:PFND - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
2 months ago marketbeat.com
Nuvation Bio Q2 Earnings Call Highlights
Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $19 to $20.
2 months ago seekingalpha.com
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.17 per share a year ago.
2 months ago prnewswire.com
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI is the most prescribed ROS1 TKI in in both first-line…
-
2 months ago benzinga.com
Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M Estimate
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 5.88 percent decrease over losses of $(0.17)…
-
2 months ago benzinga.com
Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO
Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-IIPresenter: Hidetoshi Hayashi, Kindai…
2 months ago prnewswire.com
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroups NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global…
3 months ago zacks.com
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21
HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $17 to $21.
-
3 months ago benzinga.com
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
3 months ago benzinga.com
Why Is Nuvation Bio Stock Gaining Monday?
Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.
3 months ago benzinga.com
AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday
U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings expectations. Other big gainers include NUAI, IREN, XNCR, HUT, CIFR, CLSK, NUVB, AXTI, ATEX, APLD, and…
-
3 months ago benzinga.com
Nuvation Bio Announces Positive Updated Phase 2 Data And Expansion From Safusidenib Clinical Trial In Newly-Diagnosed Grade 2 Glioma Patients Outside The U.S.
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-upNew Phase 3 study to evaluate…
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $19.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Nuvation Bio, Raises Price Target to $13
Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $12 to $13.
4 months ago benzinga.com
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.
-
4 months ago benzinga.com
Nuvation Bio Intends To Offer $200M Aggregate Principal Amount Of Convertible Senior Notes Due In 2032
Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to…
-
5 months ago benzinga.com
Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal…
-
6 months ago benzinga.com
RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target
RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $20 price target.
-
6 months ago benzinga.com
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $17 price target.